Synendos Therapeutics: Funding, Investors & Team (Sep 2026)
Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the natural functioning of the brain. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need.
Synendos Therapeutics has raised $26.2M across 1 funding round on record, the most recent a Series A of $26.2M announced in Apr 2021.
That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Synendos Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2021.
Synendos Therapeutics Funding Rounds
Synendos Therapeutics Founders and Leadership Team
Contact details for the Synendos Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Synendos Therapeutics Funding Compared to Other Health Care Startups
Synendos Therapeutics' latest round of $26.2M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Synendos Therapeutics in Health Care and Allschwil
Companies Similar to Synendos Therapeutics
MoleSense is to provide a wearable skin sensor to help monitor high-risk pregnancies.
CeQur Simplicity helps people with diabetes by developing drug-delivery devices. They develop bolus insulin…
Calmea develops advanced contactless sensing systems that invisibly track sleep and automatically modify…
NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for…
UNBOOUND is a medtech company and university spin-off (The Rockefeller University and University of Geneva)…
Christina Vallgren and Marcus Palm, two physicists from CERN, co-founded Terapet along with Professor Raymond…
Axmed is a company that specializes in serving low and middle-income countries (LMICs), with the goal of…
Babylat is an enricher device is the first automated, small-scale tabletop device for the protein enrichment…
Altiscreen is creating and producing cutting-edge, portable drug-of-abuse detection systems. With the use of…
Vivent provides growers, breeders and agrochem companies with actionable information direct from plants…
Multiwave develops breakthrough Magnetic Resonance Imaging and Positron Emission Tomography devices. Founded…
Synendos Therapeutics Funding FAQs
What does Synendos Therapeutics do?
Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the natural functioning of the brain. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need.
How much funding has Synendos Therapeutics raised?
Synendos Therapeutics has raised $26.2M across 1 round on record. The most recent is a Series A of $26.2M announced in Apr 2021.
When did Synendos Therapeutics last raise funding?
Synendos Therapeutics' most recent funding round on record is a Series A of $26.2M, announced in Apr 2021.
Who is the CEO of Synendos Therapeutics?
Andrea Chicca is listed as CEO at Synendos Therapeutics.
Where is Synendos Therapeutics headquartered?
Synendos Therapeutics is based in Allschwil, Basel-Landschaft, Switzerland.
How many employees does Synendos Therapeutics have?
Synendos Therapeutics is in the 1-10 employee band.
How does Synendos Therapeutics' funding compare to other Health Care startups?
Synendos Therapeutics' latest round of $26.2M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Synendos Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Synendos Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.